Related Experiment Video
Updated: May 12, 2026
Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Novel quinuclidinone derivatives induce apoptosis in lung cancer via sphingomyelinase pathways
A Malki1, L Fathy, E S H El Ashry
1Biochemistry department, Faculty of Science, Alexandria University, Alexandria, Egypt. ahmed.malki@gmail.com
Abstract:
We previously reported novel quinuclidinone analogs which induced apoptosis in lung and breast cancer cells. In this study, we designed and synthesized novel quinuclidinone analogs that showed cytotoxicity in lung cancer cells. The effects of these analogs were studied in H1299 human large cell lung carcinoma cells that are null for p53 and normal lung epithelial cell lines (NL-20). The effects of the analogs were investigated by MTT assay, ELISA based apoptotic assay, TUNEL assay, sphingomylinase activity, flow cytometry and western blot analysis. Our data indicated that derivatives 4 and 6 decreased cell proliferation and induced apoptosis in H1299 cells more than NL-20 cells. Derivatives 4 and 6 reduced percent of cells in G2/M phase in H1299 cells more than NL-20 cells and these results were confirmed by increased expression levels of cyclin E. Furthermore, derivatives 4 and 6 increased sphingomyelinase activity, caspase-8, and caspase-9 and JNK-1 expression level in H1299. Additionally, derivatives 4 and 6 induced Procaspase-3, PARP-1 cleavage, and increased caspase-3 activity. All these results confirm that our quinuclidinone derivatives provoke cytotoxicity in lung cancer cells through the interplay of key apoptosis molecules in different compartments of the cell beginning with an increase in sphingomyelinase activity.
Insights
Novel quinuclidinone derivatives demonstrate significant cytotoxicity against lung cancer cells by inducing apoptosis. These compounds selectively target cancer cells, offering a promising avenue for lung cancer therapy.
Area of Science:
- Medicinal Chemistry
- Cancer Biology
- Molecular Pharmacology
Background:
- Quinuclidinone analogs previously showed efficacy in inducing apoptosis in cancer cells.
- Lung cancer remains a leading cause of cancer-related mortality, necessitating novel therapeutic strategies.
Purpose of the Study:
- To design, synthesize, and evaluate novel quinuclidinone analogs for their cytotoxic effects on lung cancer cells.
- To investigate the underlying mechanisms of apoptosis induction by these analogs in p53-null H1299 lung cancer cells.
Main Methods:
- Synthesis of novel quinuclidinone analogs.
- Cytotoxicity assessment using MTT assay.
- Apoptosis evaluation via ELISA, TUNEL assay, flow cytometry, and Western blot analysis.
- Analysis of sphingomyelinase activity and key apoptosis-related protein expression.
Main Results:
- Derivatives 4 and 6 exhibited potent cytotoxicity and induced apoptosis in H1299 lung cancer cells more effectively than in normal lung epithelial cells (NL-20).
- These derivatives caused cell cycle arrest at the G2/M phase, correlating with increased cyclin E expression.
- Upregulation of sphingomyelinase activity, caspase-8, caspase-9, JNK-1, and downstream effector caspase-3, along with PARP-1 cleavage, was observed.
Conclusions:
- Novel quinuclidinone derivatives induce lung cancer cell cytotoxicity through a multi-compartmental apoptosis pathway.
- The mechanism involves the activation of sphingomyelinase and a cascade of caspases, highlighting their therapeutic potential.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...